VJHemOnc is committed to improving our service to you

MDS 2020 | Azacitidine treatment toxicities

VJHemOnc is committed to improving our service to you

Rena Buckstein

Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, discusses some of the toxicities associated with azacitidine in the treatment of higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter